BIND Therapeutics is a biotechnology company incorporated in 2006; Pfizer acquired substantially all of its assets in 2016. BIND’s product candidates were based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. ACCURINS®, which continue to be developed with Pfizer, have the potential to achieve therapeutic outcomes not currently possible with conventional treatment modalities.